NASDAQ:AVXL Anavex Life Sciences Q1 2025 Earnings Report $9.31 -0.19 (-2.00%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$9.59 +0.28 (+2.95%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Anavex Life Sciences EPS ResultsActual EPS-$0.14Consensus EPS -$0.17Beat/MissBeat by +$0.03One Year Ago EPSN/AAnavex Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnavex Life Sciences Announcement DetailsQuarterQ1 2025Date2/12/2025TimeBefore Market OpensConference Call DateWednesday, February 12, 2025Conference Call Time8:30AM ETUpcoming EarningsAnavex Life Sciences' Q2 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Anavex Life Sciences Q1 2025 Earnings Call TranscriptProvided by QuartrFebruary 12, 2025 ShareLink copied to clipboard.PresentationSkip to Participants Clint TomlinsonInvestor Relations at Anavex Life Sciences00:00:00Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal twenty twenty five First Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen only mode, and later, we will conduct a question and answer session. During this session, if you would like to ask a question, please use the Q and A box or raise your hand. Note that this conference is being recorded. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:00:24The call will be available for replay on Anavex's website at www.anavex.com. With us today is Doctor. Christopher Missling, President and Chief Executive Officer and Sondra Bernish, Principal Financial Officer. Before we begin, please note that this conference call, the company will make some projections and forward looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:00:52We encourage you to review the company's filings with the SEC. This includes without limitation the company's forms 10 ks and 10 Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward looking statements. These factors may include without limitation risks inherent in the development and or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. And with that, I'd like to turn the call over to doctor Missling. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:01:29Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. I would like to point out that we are receiving growing support from stakeholders for the potential to advance a novel precision medicine treatment for early Alzheimer disease with convenient oral dosing and with potential clinical meaningful benefit. We are excited to be potentially making a difference for individuals suffering from Alzheimer disease by presenting a scalable treatment alternative alongside the ease of oral administration. Last month, we provided top line long term data from the phase two b slash three attention AD open label extension trial. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:02:19The data demonstrated that over three years of continuous treatment with plaqueminesine significantly reduced clinical decline, showing continued clinical meaningful benefit for early Alzheimer disease patients. Also in January, we announced that the Journal of Prevention of Alzheimer Disease, JPET, published a peer reviewed detailed results from the Phase IIbthree study, evaluating oral blecharmazine for the treatment of early Alzheimer disease. Once daily oral blackamazine demonstrating a safety profile with no associated neuroimaging adverse events significantly slowed clinical progression by thirty six point three percent at forty eight weeks with plaquami gene group, as well as the prespecified sigma one wild type gene group by forty nine point eight percent at forty eight weeks on the prespecified primary cognitive endpoint, ADAS COG13, respectively. The peer reviewed publication of this data underscores the significance of the findings for both the scientific community and those focused on Alzheimer disease. Alzheimer disease is a highly complex condition, and this dataset plays a crucial role in advancing our understanding of the phase two b slash three results. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:03:41We are grateful for the dedication from participants, the families, and the sites for taking part in this important study. Finally, at the January, we announced that Anavex was issued a new composition of meta US patent expected to remain in force at least until July 2039 entitled A2seventy three Crystalline Polymorph compositions of meta and method of use thereof from the United States Patent and Trademark Office. This new patent claims crystalline forms of the dihydrogen phosphate salt of Anavex two seventy three free base, as well as transdermal patches and etheric coated oral dosage forms, including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer's disease, Parkinson Parkinson disease, and other disorders. The issuance of this US patent again showcases our expertise in identifying and pursuing novel therapeutic forms and formulations that are rooted in science. With respect to ANAVEX371, which will now include more participants at the longer treatment duration within Part b, ANAVEX expects data from the ongoing Part b of the placebo controlled Phase two study in schizophrenia in the first half of twenty twenty five. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:05:16And now I would like to direct the call to Sandeep Boerneisch, Principal Financial Officer of Anavex, for a financial summary of the recently reported quarter. Sandra BoenischPrincipal Financial Officer at Anavex Life Sciences00:05:27Thank you, Christopher. Good morning, everyone. I'm pleased to share with you today our first quarter financial results for the 2025 fiscal year. Our cash position at December 31 was $120,800,000 and we had no debt. During the quarter, we utilized cash and cash equivalents of $12,100,000 in operating activities after taking into account changes in noncash working capital accounts. Sandra BoenischPrincipal Financial Officer at Anavex Life Sciences00:05:54As of quarter end, we anticipate at the current cash utilization rate and range a runway of approximately four years. During our most recent quarter, general and administrative expenses were $3,100,000 as compared to $2,700,000 for the comparable first quarter. Our research and development expenses for the quarter were $10,400,000 as compared to $8,700,000 for the comparable first quarter. And lastly, we reported a net loss of $12,100,000 for the quarter or $0.14 per share. Thanks. Sandra BoenischPrincipal Financial Officer at Anavex Life Sciences00:06:26And back to you, Christopher. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:06:28Thank you, Sandra. In summary, we are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer disease with convenient oral dosing and with potential clinically meaningful benefit. We are very excited to be potentially making a difference for individuals suffering from Alzheimer's disease by presenting a scalable treatment alternative alongside the ease of all administration using precision medicine. I would now like to turn the call back to Clint for Q and A. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:07:03Thank you, Christopher. And it looks like the first question is coming from Tom Bishop. Hold, please. Tom, can you hear us? Now. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:07:35I can hear you now, Tom. Tom BishopAnalyst at BI Research00:07:37Good. With regards to the next few months, I guess we're hoping for some word from Europe around midyear or is that the timeline? I thought I heard six months, but then there's then I heard maybe it could be longer. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:07:58So we will expect the review to take two ten days since filing, which was in November, and it was accepted in December the following months, less than thirty days after the filing. So we are prepared for this review, and we're looking forward to it. Tom BishopAnalyst at BI Research00:08:19So that would be, like, July ish or maybe September? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:08:24We expect the feedback for the review to complete it in by the end of this year. I don't know more specifics at this time. So that's why we are right there for. Tom BishopAnalyst at BI Research00:08:37Okay. Now was there any discussion about a priority review of any sort, or that ship has sailed? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:08:46The requirement for that is a prime status. And since we filed without the prime because we were encouraged to file without the prime because of the unmet need, this is a procedure which is 250,000. Okay. Tom BishopAnalyst at BI Research00:09:04Also, what are the upcoming events that we can look forward to? I guess, we have the three seventy one trial due sometime before by midyear? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:09:21That's correct. So we expect the ANAVEX three seventy one schizophrenia readout, as we mentioned, in the first half of this year. Then we also are expecting a scientific presentation of detailed data of the open label extension study, attention AD in April at the ADPD conference, which we top lined last month, and the details will be presented at this conference. And further, we will provide updates on the pipeline. We expect updates on the Parkinson's disease program and other subsequent programs as well. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:10:12Tom, we don't hear you. Tom BishopAnalyst at BI Research00:10:15You said you are receiving, increasing interest or increasing support. And I was just wondering if you could elaborate elaborate on that. Uh-oh. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:10:27We are getting support from stakeholders, that is advocacy groups across the board, and that's very encouraging in because the unmet need in the current limited availability of scalable drugs for this horrible condition, and that is includes advocacy group in Europe and around the globe. Tom BishopAnalyst at BI Research00:10:56Okay. And how about from other pharmaceutical companies? I mean, if this was approved, you need to file you need to start to market it in Europe and produce it and all that. And I guess, you know, one thing people point to is that there has been no hint yet of any interest from a pharma company. So just wondering I think the company has just been quiet about it. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:11:22Yes. That's not accurate, of course. There's ongoing discussions, and we initiated that last month at JPMorgan. And also regarding the material for marketing the drug, we have enough supply for launching this drug. The manufacturing has been extremely productive to have marketed product ready for the market entry. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:11:52Regarding how to move forward in terms of a sales force or a partnership with a pharma company, this is deciding on the terms of those discussions, and the deciding factor guiding factor will be creating the most shareholder value for shareholders. So whatever is in the interest of shareholders, that path will be taken. But there's no doubt if there's a drug approved for such an indication, there will be a lot of interest. Tom BishopAnalyst at BI Research00:12:26Also, what is the status of Rett? Rett Syndrome? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:12:30Rett Syndrome, we decided to and we said it a while ago, we plan to do another study to reconfirm and a larger study given that last study was short on number of patients and the placebo arm was small giving some volatility in the endpoints. So we are planning to do another study in Rett syndrome as well. And this is one of what I refer to updates will come, accordingly throughout this year. Tom BishopAnalyst at BI Research00:13:02Okay. It's been a while since that last trial ended, so I just wondering what, what's the Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:13:08We align with the courses and we also like to focus on what is most creating most value right now. This is the Ultima program and the filing of the Ultima indication was the most priority for us last few months. Tom BishopAnalyst at BI Research00:13:24Okay. And you mentioned the crystalline patent. And I was just wondering what, how significant is that? It was hard to tell. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:13:35It's actually very significant. And I think that should be pointed out. Thanks for asking the question that this crystallized patent API was actually used in all prior clinical studies. So it's not a new patent which has been suddenly, you know, identified as a patentable composition of matter, but these trials which we ran in Alzheimer's disease were all utilizing these composition of matter of the patent, which expires at the earliest, in July 2038 02/1939. And that's very important because that means our composition of meta is protected for the entire spectrum of these indications, including Alzheimer disease as well as Parkinson's disease for the for the capsule or the tablets used with the respective API, which will be the case as well in the market. Tom BishopAnalyst at BI Research00:14:48That is very good news then. Also, any update on Parkinson? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:14:55Yeah. As I said, we will update Parkinson program. We had interaction with regulatory bodies, and we will provide an update accordingly shortly about how to proceed with Parkinson disease program. Tom BishopAnalyst at BI Research00:15:09Anything on the FDA as far as glaucomeracine goes? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:15:14We for Alzheimer disease, we are planning to have a meeting, and that is what we did with EMA with the dialogue, with a very open dialogue in a meeting to request and share the data and asking what is the recommended procedure for us to proceed. And we're looking forward to this interaction. Tom BishopAnalyst at BI Research00:15:35Okay. Great. And are the OLE patients still on the drug? Or Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:15:39They are actually. And we mentioned it at the last press release when we mentioned the OLE data that the seventy four people, participants are still on study drug as a comp on a compassionate use program, and we will also follow-up with them for real world evidence. And we expect data from that as well going forward. So that's very encouraging that after four years of total intake of the drug in the placebo controlled part as well as in the open label part, patients still continue to take the drug and are requesting to be on study drug. And we are able for that reason to use this additional population for real world evidence potentially. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:16:26And so far, nobody died from the drug in our study and outside of the study, and that's actually preceded the phase two slash three that includes also the phase two a, which started over nine years ago. So over nine years, there has been no debt in, caused by the drug. Tom BishopAnalyst at BI Research00:16:45You know, the drug is just amazing in its advantages over these infusion therapy drugs. And it's just, you know, I'm very excited. Well, thank you for answering my questions. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:16:58Thank you. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:17:01Thank you, Tom. There's another question here, Doctor. Missling, if you wanted to expand on that, if you want to expand on that, the a brief overview of efficacy compared to the monoclonal antibodies? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:17:19So it's important to point out that there's a requirement for clinically meaningfulness and that's been recently published in our paper twenty twenty four, which we also pointed out or cited in one of the last press releases on the efficacy data on the open label as well as the paper publication on jpad. And that threshold is a a two point score or more delta of ADASCOG. And we demonstrated in our trials a AddisCOX thirteen of 2.03 for the entire population, all participants. That means we are clinic clearly clinically meaningful because that means that a patient, a participant can identify these changes himself, herself, but also the caregiver can identify these changes, as well as the physician can identify these changes. And every score less than that would be not identifiable. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:18:22And to put this in perspective, our ATLAS COG 13 over forty eight weeks reached that level of two point or more. And in comparison, Kizunla or Donanamab from Lilly reached for the Adascoq thirteen exactly the same score, a score only of 1.35 delta to placebo, and that would not meet the clinically meaningful threshold of two point or more. And it was also reached after a much longer period of time, this 1.35. So we are better and earlier in identifying improvement compared to placebo with plaqueminesine. And that comes on top of the advantage of a oral once daily administration, which is, mechanistically probably closer to the complexity or origination of the disease, which is ahead or earlier than a beta in tau aggregation and inflammation and other dysfunctions, which are within this disease than other drugs, including the monoclonal antibodies, which are targeting further downstream limited pathways, for example, the A beta pathway, which has recently gotten in a bit of critique because of the focus on this and the support, which was criticized in some media recently as well. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:19:57But there's no doubt that we are happy to consider glacamizine as a potentially complementary to existing treatments that includes the antibodies, but also existing treatments, which is donepezil and memantine, which was demonstrated in our trial to be on the data was on top of Placamazine, on top of Donepezil and Memantine. So our effect is basically on top of standard of care available at the time of the of the trial. But again, the key thing is that the scalability, the ecosystem of the healthcare would be better suited with oral ones daily. And given its ability not to cause serious deaths is the antibodies are doing, and that's why they have a black box warning. That means you can die from this drug in case of the antibodies. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:21:02And you need to have a physician which has to be very courageous to prescribe this drug. And given that it has to monitor the effect on the patient very carefully and requires a mandatory MRI every three weeks. And this requires contrast medium. It's not a trivial task also to find appointment for an MRI. And MRI centers are not widely spread out. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:21:32In the Midwest. You have defied any. And that is probably also the contribution of slow uptake of the antibodies and the limited ability to expand this into a broader patient population with diverse background and location. That would be overcome with oral once daily small molecule like the bacamecine, of course. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:21:56Well, thank you for that. Another question, and I think it's the last one here is, assuming an EMA approval, what other countries may follow and open the markets to glaucomaecine? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:22:15So we are planning to submit to other jurisdictions, among them in The UK and others, Canada and Australia have been also participating in this trial. That will probably happen before the end of the year. So we're expanding this, and I mentioned the plan for The U. S. As well, which will be a dialogue with the agency as well. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:22:38So we're expanding the jurisdictions of beyond EMA because of the unmet need. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:22:48Excellent. Thank you. I believe that's all the questions at this time, Doctor. Messon. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:22:56Thank you. So in closing, we'd like to continue to focus on execution and commercial readiness as we advance our therapeutic pipeline to potentially improve patients' lives with these devastating conditions. I'd like to thank you for your attention. Thank you. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:23:16Thank you, everyone, for joining the call today. This concludes our conference call. We appreciate your participation. You may now disconnect.Read moreParticipantsExecutivesClint TomlinsonInvestor RelationsChristopher MisslingPresident & Chief Executive OfficerAnalystsSandra BoenischPrincipal Financial Officer at Anavex Life SciencesTom BishopAnalyst at BI ResearchPowered by Conference Call Audio Live Call not available Earnings Conference CallAnavex Life Sciences Q1 202500:00 / 00:00Speed:1x1.25x1.5x2xTranscript SectionsPresentationParticipants Earnings DocumentsQuarterly report(10-Q) Anavex Life Sciences Earnings HeadlinesAnavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of SchizophreniaMay 1 at 7:30 AM | globenewswire.comAnavex Life Sciences to Participate in The Citizens Life Sciences ConferenceApril 30 at 7:30 AM | globenewswire.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 2, 2025 | Brownstone Research (Ad)Anavex appoints Audrey Gabelle to Scientific Advisory BoardApril 24, 2025 | markets.businessinsider.comAnavex Life Sciences Corp.: Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory BoardApril 23, 2025 | finanznachrichten.deAnavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory BoardApril 23, 2025 | globenewswire.comSee More Anavex Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anavex Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anavex Life Sciences and other key companies, straight to your email. Email Address About Anavex Life SciencesAnavex Life Sciences (NASDAQ:AVXL), a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.View Anavex Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Microsoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of EarningsAmazon's Earnings Will Make or Break the Stock's Comeback CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock Up Upcoming Earnings Palantir Technologies (5/5/2025)Vertex Pharmaceuticals (5/5/2025)Realty Income (5/5/2025)Williams Companies (5/5/2025)CRH (5/5/2025)Advanced Micro Devices (5/6/2025)American Electric Power (5/6/2025)Constellation Energy (5/6/2025)Marriott International (5/6/2025)Energy Transfer (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PresentationSkip to Participants Clint TomlinsonInvestor Relations at Anavex Life Sciences00:00:00Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal twenty twenty five First Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen only mode, and later, we will conduct a question and answer session. During this session, if you would like to ask a question, please use the Q and A box or raise your hand. Note that this conference is being recorded. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:00:24The call will be available for replay on Anavex's website at www.anavex.com. With us today is Doctor. Christopher Missling, President and Chief Executive Officer and Sondra Bernish, Principal Financial Officer. Before we begin, please note that this conference call, the company will make some projections and forward looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:00:52We encourage you to review the company's filings with the SEC. This includes without limitation the company's forms 10 ks and 10 Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward looking statements. These factors may include without limitation risks inherent in the development and or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. And with that, I'd like to turn the call over to doctor Missling. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:01:29Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. I would like to point out that we are receiving growing support from stakeholders for the potential to advance a novel precision medicine treatment for early Alzheimer disease with convenient oral dosing and with potential clinical meaningful benefit. We are excited to be potentially making a difference for individuals suffering from Alzheimer disease by presenting a scalable treatment alternative alongside the ease of oral administration. Last month, we provided top line long term data from the phase two b slash three attention AD open label extension trial. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:02:19The data demonstrated that over three years of continuous treatment with plaqueminesine significantly reduced clinical decline, showing continued clinical meaningful benefit for early Alzheimer disease patients. Also in January, we announced that the Journal of Prevention of Alzheimer Disease, JPET, published a peer reviewed detailed results from the Phase IIbthree study, evaluating oral blecharmazine for the treatment of early Alzheimer disease. Once daily oral blackamazine demonstrating a safety profile with no associated neuroimaging adverse events significantly slowed clinical progression by thirty six point three percent at forty eight weeks with plaquami gene group, as well as the prespecified sigma one wild type gene group by forty nine point eight percent at forty eight weeks on the prespecified primary cognitive endpoint, ADAS COG13, respectively. The peer reviewed publication of this data underscores the significance of the findings for both the scientific community and those focused on Alzheimer disease. Alzheimer disease is a highly complex condition, and this dataset plays a crucial role in advancing our understanding of the phase two b slash three results. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:03:41We are grateful for the dedication from participants, the families, and the sites for taking part in this important study. Finally, at the January, we announced that Anavex was issued a new composition of meta US patent expected to remain in force at least until July 2039 entitled A2seventy three Crystalline Polymorph compositions of meta and method of use thereof from the United States Patent and Trademark Office. This new patent claims crystalline forms of the dihydrogen phosphate salt of Anavex two seventy three free base, as well as transdermal patches and etheric coated oral dosage forms, including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer's disease, Parkinson Parkinson disease, and other disorders. The issuance of this US patent again showcases our expertise in identifying and pursuing novel therapeutic forms and formulations that are rooted in science. With respect to ANAVEX371, which will now include more participants at the longer treatment duration within Part b, ANAVEX expects data from the ongoing Part b of the placebo controlled Phase two study in schizophrenia in the first half of twenty twenty five. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:05:16And now I would like to direct the call to Sandeep Boerneisch, Principal Financial Officer of Anavex, for a financial summary of the recently reported quarter. Sandra BoenischPrincipal Financial Officer at Anavex Life Sciences00:05:27Thank you, Christopher. Good morning, everyone. I'm pleased to share with you today our first quarter financial results for the 2025 fiscal year. Our cash position at December 31 was $120,800,000 and we had no debt. During the quarter, we utilized cash and cash equivalents of $12,100,000 in operating activities after taking into account changes in noncash working capital accounts. Sandra BoenischPrincipal Financial Officer at Anavex Life Sciences00:05:54As of quarter end, we anticipate at the current cash utilization rate and range a runway of approximately four years. During our most recent quarter, general and administrative expenses were $3,100,000 as compared to $2,700,000 for the comparable first quarter. Our research and development expenses for the quarter were $10,400,000 as compared to $8,700,000 for the comparable first quarter. And lastly, we reported a net loss of $12,100,000 for the quarter or $0.14 per share. Thanks. Sandra BoenischPrincipal Financial Officer at Anavex Life Sciences00:06:26And back to you, Christopher. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:06:28Thank you, Sandra. In summary, we are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer disease with convenient oral dosing and with potential clinically meaningful benefit. We are very excited to be potentially making a difference for individuals suffering from Alzheimer's disease by presenting a scalable treatment alternative alongside the ease of all administration using precision medicine. I would now like to turn the call back to Clint for Q and A. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:07:03Thank you, Christopher. And it looks like the first question is coming from Tom Bishop. Hold, please. Tom, can you hear us? Now. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:07:35I can hear you now, Tom. Tom BishopAnalyst at BI Research00:07:37Good. With regards to the next few months, I guess we're hoping for some word from Europe around midyear or is that the timeline? I thought I heard six months, but then there's then I heard maybe it could be longer. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:07:58So we will expect the review to take two ten days since filing, which was in November, and it was accepted in December the following months, less than thirty days after the filing. So we are prepared for this review, and we're looking forward to it. Tom BishopAnalyst at BI Research00:08:19So that would be, like, July ish or maybe September? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:08:24We expect the feedback for the review to complete it in by the end of this year. I don't know more specifics at this time. So that's why we are right there for. Tom BishopAnalyst at BI Research00:08:37Okay. Now was there any discussion about a priority review of any sort, or that ship has sailed? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:08:46The requirement for that is a prime status. And since we filed without the prime because we were encouraged to file without the prime because of the unmet need, this is a procedure which is 250,000. Okay. Tom BishopAnalyst at BI Research00:09:04Also, what are the upcoming events that we can look forward to? I guess, we have the three seventy one trial due sometime before by midyear? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:09:21That's correct. So we expect the ANAVEX three seventy one schizophrenia readout, as we mentioned, in the first half of this year. Then we also are expecting a scientific presentation of detailed data of the open label extension study, attention AD in April at the ADPD conference, which we top lined last month, and the details will be presented at this conference. And further, we will provide updates on the pipeline. We expect updates on the Parkinson's disease program and other subsequent programs as well. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:10:12Tom, we don't hear you. Tom BishopAnalyst at BI Research00:10:15You said you are receiving, increasing interest or increasing support. And I was just wondering if you could elaborate elaborate on that. Uh-oh. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:10:27We are getting support from stakeholders, that is advocacy groups across the board, and that's very encouraging in because the unmet need in the current limited availability of scalable drugs for this horrible condition, and that is includes advocacy group in Europe and around the globe. Tom BishopAnalyst at BI Research00:10:56Okay. And how about from other pharmaceutical companies? I mean, if this was approved, you need to file you need to start to market it in Europe and produce it and all that. And I guess, you know, one thing people point to is that there has been no hint yet of any interest from a pharma company. So just wondering I think the company has just been quiet about it. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:11:22Yes. That's not accurate, of course. There's ongoing discussions, and we initiated that last month at JPMorgan. And also regarding the material for marketing the drug, we have enough supply for launching this drug. The manufacturing has been extremely productive to have marketed product ready for the market entry. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:11:52Regarding how to move forward in terms of a sales force or a partnership with a pharma company, this is deciding on the terms of those discussions, and the deciding factor guiding factor will be creating the most shareholder value for shareholders. So whatever is in the interest of shareholders, that path will be taken. But there's no doubt if there's a drug approved for such an indication, there will be a lot of interest. Tom BishopAnalyst at BI Research00:12:26Also, what is the status of Rett? Rett Syndrome? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:12:30Rett Syndrome, we decided to and we said it a while ago, we plan to do another study to reconfirm and a larger study given that last study was short on number of patients and the placebo arm was small giving some volatility in the endpoints. So we are planning to do another study in Rett syndrome as well. And this is one of what I refer to updates will come, accordingly throughout this year. Tom BishopAnalyst at BI Research00:13:02Okay. It's been a while since that last trial ended, so I just wondering what, what's the Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:13:08We align with the courses and we also like to focus on what is most creating most value right now. This is the Ultima program and the filing of the Ultima indication was the most priority for us last few months. Tom BishopAnalyst at BI Research00:13:24Okay. And you mentioned the crystalline patent. And I was just wondering what, how significant is that? It was hard to tell. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:13:35It's actually very significant. And I think that should be pointed out. Thanks for asking the question that this crystallized patent API was actually used in all prior clinical studies. So it's not a new patent which has been suddenly, you know, identified as a patentable composition of matter, but these trials which we ran in Alzheimer's disease were all utilizing these composition of matter of the patent, which expires at the earliest, in July 2038 02/1939. And that's very important because that means our composition of meta is protected for the entire spectrum of these indications, including Alzheimer disease as well as Parkinson's disease for the for the capsule or the tablets used with the respective API, which will be the case as well in the market. Tom BishopAnalyst at BI Research00:14:48That is very good news then. Also, any update on Parkinson? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:14:55Yeah. As I said, we will update Parkinson program. We had interaction with regulatory bodies, and we will provide an update accordingly shortly about how to proceed with Parkinson disease program. Tom BishopAnalyst at BI Research00:15:09Anything on the FDA as far as glaucomeracine goes? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:15:14We for Alzheimer disease, we are planning to have a meeting, and that is what we did with EMA with the dialogue, with a very open dialogue in a meeting to request and share the data and asking what is the recommended procedure for us to proceed. And we're looking forward to this interaction. Tom BishopAnalyst at BI Research00:15:35Okay. Great. And are the OLE patients still on the drug? Or Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:15:39They are actually. And we mentioned it at the last press release when we mentioned the OLE data that the seventy four people, participants are still on study drug as a comp on a compassionate use program, and we will also follow-up with them for real world evidence. And we expect data from that as well going forward. So that's very encouraging that after four years of total intake of the drug in the placebo controlled part as well as in the open label part, patients still continue to take the drug and are requesting to be on study drug. And we are able for that reason to use this additional population for real world evidence potentially. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:16:26And so far, nobody died from the drug in our study and outside of the study, and that's actually preceded the phase two slash three that includes also the phase two a, which started over nine years ago. So over nine years, there has been no debt in, caused by the drug. Tom BishopAnalyst at BI Research00:16:45You know, the drug is just amazing in its advantages over these infusion therapy drugs. And it's just, you know, I'm very excited. Well, thank you for answering my questions. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:16:58Thank you. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:17:01Thank you, Tom. There's another question here, Doctor. Missling, if you wanted to expand on that, if you want to expand on that, the a brief overview of efficacy compared to the monoclonal antibodies? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:17:19So it's important to point out that there's a requirement for clinically meaningfulness and that's been recently published in our paper twenty twenty four, which we also pointed out or cited in one of the last press releases on the efficacy data on the open label as well as the paper publication on jpad. And that threshold is a a two point score or more delta of ADASCOG. And we demonstrated in our trials a AddisCOX thirteen of 2.03 for the entire population, all participants. That means we are clinic clearly clinically meaningful because that means that a patient, a participant can identify these changes himself, herself, but also the caregiver can identify these changes, as well as the physician can identify these changes. And every score less than that would be not identifiable. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:18:22And to put this in perspective, our ATLAS COG 13 over forty eight weeks reached that level of two point or more. And in comparison, Kizunla or Donanamab from Lilly reached for the Adascoq thirteen exactly the same score, a score only of 1.35 delta to placebo, and that would not meet the clinically meaningful threshold of two point or more. And it was also reached after a much longer period of time, this 1.35. So we are better and earlier in identifying improvement compared to placebo with plaqueminesine. And that comes on top of the advantage of a oral once daily administration, which is, mechanistically probably closer to the complexity or origination of the disease, which is ahead or earlier than a beta in tau aggregation and inflammation and other dysfunctions, which are within this disease than other drugs, including the monoclonal antibodies, which are targeting further downstream limited pathways, for example, the A beta pathway, which has recently gotten in a bit of critique because of the focus on this and the support, which was criticized in some media recently as well. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:19:57But there's no doubt that we are happy to consider glacamizine as a potentially complementary to existing treatments that includes the antibodies, but also existing treatments, which is donepezil and memantine, which was demonstrated in our trial to be on the data was on top of Placamazine, on top of Donepezil and Memantine. So our effect is basically on top of standard of care available at the time of the of the trial. But again, the key thing is that the scalability, the ecosystem of the healthcare would be better suited with oral ones daily. And given its ability not to cause serious deaths is the antibodies are doing, and that's why they have a black box warning. That means you can die from this drug in case of the antibodies. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:21:02And you need to have a physician which has to be very courageous to prescribe this drug. And given that it has to monitor the effect on the patient very carefully and requires a mandatory MRI every three weeks. And this requires contrast medium. It's not a trivial task also to find appointment for an MRI. And MRI centers are not widely spread out. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:21:32In the Midwest. You have defied any. And that is probably also the contribution of slow uptake of the antibodies and the limited ability to expand this into a broader patient population with diverse background and location. That would be overcome with oral once daily small molecule like the bacamecine, of course. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:21:56Well, thank you for that. Another question, and I think it's the last one here is, assuming an EMA approval, what other countries may follow and open the markets to glaucomaecine? Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:22:15So we are planning to submit to other jurisdictions, among them in The UK and others, Canada and Australia have been also participating in this trial. That will probably happen before the end of the year. So we're expanding this, and I mentioned the plan for The U. S. As well, which will be a dialogue with the agency as well. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:22:38So we're expanding the jurisdictions of beyond EMA because of the unmet need. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:22:48Excellent. Thank you. I believe that's all the questions at this time, Doctor. Messon. Christopher MisslingPresident & Chief Executive Officer at Anavex Life Sciences00:22:56Thank you. So in closing, we'd like to continue to focus on execution and commercial readiness as we advance our therapeutic pipeline to potentially improve patients' lives with these devastating conditions. I'd like to thank you for your attention. Thank you. Clint TomlinsonInvestor Relations at Anavex Life Sciences00:23:16Thank you, everyone, for joining the call today. This concludes our conference call. We appreciate your participation. You may now disconnect.Read moreParticipantsExecutivesClint TomlinsonInvestor RelationsChristopher MisslingPresident & Chief Executive OfficerAnalystsSandra BoenischPrincipal Financial Officer at Anavex Life SciencesTom BishopAnalyst at BI ResearchPowered by